All In Biotech

Drug Trial Radar · NCT02640157

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

506

Actual

Start

Dec 2015

Primary completion

Oct 2016

Study completion Feb 2017

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.

Conditions

  • Chronic Hepatitis C
  • Hepatitis C Virus
  • Genotype 3 Hepatitis C Virus

Interventions

  • ABT-493/ABT-530Drug

    Tablet; ABT-493 coformulated with ABT-530

  • SofosbuvirDrug

    Tablet

  • DaclatasvirDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm A to Arm BTime frame: 12 weeks after the last actual dose of study drug
  2. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm C to Arm ATime frame: 12 weeks after the last actual dose of study drug

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.